Skip to main content
SpringerLink
Log in

Etravirine: A Guide to Its Use in Treatment-Experienced Pediatric Patients with HIV-1 Infection in the US

  • Adis Drug Clinical Q&A
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Etravirine (Intelence®), an oral next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is approved for the treatment of HIV-1 infection in treatment-experienced patients. In the US, the approved use of etravirine in patients who have evidence of viral replication and harbor HIV-1 strains resistant to other antiretroviral agents has recently been expanded to include pediatric patients aged ≥6 to <18 years. At 24 and 48 weeks in an open-label trial, etravirine 5.2mg/kg twice daily (maximum dosage 200 mg twice daily) plus an optimized background therapy regimen achieved complete viral response (defined as HIV-1 RNA <50 copies/mL) in approximately half of treatment-experienced children and adolescents with HIV-1 infection and evidence of viral replication, and had an acceptable tolerability profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda (MD): US Department of Health and Human Services, 2011 Aug 11.

    Google Scholar 

  2. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012 Jun 5; 156 (11): 817–33.

    Article  PubMed  Google Scholar 

  3. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006 Apr 1; 41 (4): 439–46.

    Article  PubMed  Google Scholar 

  4. Penazzato M, Giaquinto C. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children. Drugs 2011; 71 (16): 2131–49.

    Article  PubMed  CAS  Google Scholar 

  5. Croxtall JD. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. Drugs 2012; 72 (6): 847–69.

    Article  PubMed  CAS  Google Scholar 

  6. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370 (9581): 29–38.

    Article  PubMed  CAS  Google Scholar 

  7. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 350 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370 (9581): 39–48.

    Article  PubMed  CAS  Google Scholar 

  8. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23 (17): 2289–300.

    Article  PubMed  CAS  Google Scholar 

  9. Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antiviral Ther 2010; 15 (7): 1045–52.

    Article  CAS  Google Scholar 

  10. Intelence® (etravirine) tablets for oral use: US prescribing information. Titusville (NJ): Janssen Pharmaceuticals, Inc., 2012 Mar.

  11. Figueiredo A, Moore KL, Mak J, et al. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog 2006 Nov; 2 (11): e1 19.

    Article  Google Scholar 

  12. Das K, Clark Jr AD, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004 May 6; 47 (10): 2550–60.

    Article  PubMed  CAS  Google Scholar 

  13. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 2010; 20; 24 (4): 503–14.

    Article  PubMed  CAS  Google Scholar 

  14. Tambuyzer L, Nijs S, Daems B, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011 Sep 1; 58 (1): 18–22.

    Article  PubMed  CAS  Google Scholar 

  15. Fulco PP, McNicholl IR. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy 2009 Mar; 29 (3): 281–94.

    Article  PubMed  CAS  Google Scholar 

  16. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents: PIANO 48-week results [abstract no. TUAB0204]. AIDS 2012: XIX International AIDS Conference; 2012 Jul 22–27; Washington, DC.

  17. Schöller-Gyüre M, Kakuda TN, Van Solingen-Ristea RM, et al. Bioavailability of the 100 mg etravirine tablet dispersed in water and of the 25 mg pediatric tablet formulation [abstract plus poster no. MOPE0184]. AIDS 2008: XVII International AIDS Conference; 2008 Aug 3–8; Mexico City 18. Kakuda A, Green B, Morrish G, et al. Population pharmacokinetics of etravirine in HIV-1-infected treatment-experienced children and adolescents (6–17 years): week 24 primary analysis of the phase II PIANO trial [abstract plus poster no. TULPE026]. 6th International AIDS Society Conference on HIV Pathogenesis, treatment and prevention; 2011 Jul 17–20; Rome.

  18. Königs C, Feiterna-Sperling C, Esposito S, et al. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-infected children and adolescents. AIDS 2012 Feb; 26 (4): 447–55.

    Article  PubMed  Google Scholar 

  19. Tudor-Williams G, Cahn P, Chokephaibulkit K, Fourie J, et al. Safety and efficacy of HIV-1-infected, treatment-experienced children and adolescents (6–17 years): week 24 primary analysis of the phase II PIANO study [abstract plus poster no. TULPE027]. 6th International AIDS Society Conference on HIV Pathogenesis, treatment and prevention; 2011 Jul 17–20; Rome.

  20. Briz V, Palladino C, Navarro M, et al. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. HIV Med 2011 Aug; 12 (7): 442–6.

    Article  PubMed  CAS  Google Scholar 

  21. AIDS info. Guidelines for the use of antiretroviral agents in pediatric HIV infection [online]. Available from: URL: http://www.aidsinfo.nih.gov/con/lvguidelines/pediatricguidelines.pdf [Accessed 2012 Jun 13]

  22. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 7].

Download references

Acknowledgments and Disclosures

This article was reviewed by R. ter Heine, Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, the Netherlands.

The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A. Etravirine: A Guide to Its Use in Treatment-Experienced Pediatric Patients with HIV-1 Infection in the US. Pediatr Drugs 14, 345–350 (2012). https://doi.org/10.1007/BF03262240

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262240

Keywords

Search

Navigation